Sphingolipids and inflammatory biomarkers of COPD progression in healthy smokers
健康吸烟者 COPD 进展的鞘脂和炎症生物标志物
基本信息
- 批准号:8997390
- 负责人:
- 金额:$ 39.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-15 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:Biological MarkersBloodBlood ProteinsBlood specimenCCL20 geneCause of DeathCeramidesChronicChronic Obstructive Airway DiseaseClinicalDataDevelopmentDiagnosisDiagnostic testsDiseaseDisease ProgressionDistalEarly InterventionEarly treatmentFibrinogenGelatinase BGeneticGenetic studyGenotypeGoalsHigh Resolution Computed TomographyInflammatoryIntercellular adhesion molecule 1Interleukin-6InternationalIntervention StudiesKnowledgeLipidsLongitudinal StudiesLung diseasesMeasuresMedical GeneticsMinorityModelingMolecular ProfilingObstructionOnset of illnessPhenotypePlasmaPreventionProteinsProteomicsPublishingPulmonary EmphysemaPulmonary Surfactant-Associated Protein DResearchRespiratory physiologyRiskRisk FactorsSamplingSmokerSmokingSpecimenSphingolipidsSphingomyelinsSwedenTestingTimeTumor Necrosis Factor-alphaUnited StatesWorkX-Ray Computed Tomographyabstractingadiponectinblood lipidclinical phenotypecohortdisorder riskfollow-upgenetic associationgenome wide association studygenome-wideimaging biomarkerimprovedmolecular phenotypenovelnovel diagnosticspreventpublic health relevanceresearch studysmoking cessation
项目摘要
DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is the 3rd leading cause of death in the US1, 2. Although COPD occurs predominantly in smokers, it is unknown why only a minority of smokers (~20-40%) develop chronic airflow limitation or destruction of distal airspaces (emphysema). Furthermore, most subjects will spend many years in a presymptomatic disease state (pre-COPD) before the onset of disease, even after smoking cessation. Identification of the at-risk presymptomatic current or former smoker is the crucial firt step needed to study early interventions that can prevent the development of COPD and emphysema. In pilot work we have identified multiple novel blood lipid (sphingomyelin and ceramide species) and protein biomarkers of COPD and emphysema. We hypothesize that some of these biomarkers will be stable molecular signature that can identify presymptomatic current and former smokers who are at risk for progression to symptomatic lung disease such as COPD and emphysema. Our proposal will measure candidate biomarkers in previously collected blood from three international longitudinal cohorts (COPDGene, SPIROMICS, and Big3) that contain large numbers of pre-symptomatic former or current smokers without COPD or emphysema, who have genome wide genotyping, and are followed 3-5 years with extensive clinical phenotyping including lung function and qHRCT. The first aim will identify which biomarkers are association with progression of airflow limitation and emphysema in those who do not have COPD at baseline. The second aim will investigate whether these signatures are stable over time and identify the genetic associations contributing to the biomarker signature.
描述(由申请人提供):慢性阻塞性肺疾病(COPD)是美国第三大死亡原因1,2。尽管COPD主要发生在吸烟者中,但尚不清楚为什么只有少数吸烟者(约20-40%)会出现慢性气流受限或远端气腔破坏(肺气肿)。此外,大多数受试者在疾病发作前,甚至在戒烟后,将在症状前疾病状态(COPD前)中度过许多年。识别有症状前风险的吸烟者或既往吸烟者是研究预防COPD和肺气肿发展的早期干预措施所需的关键第一步。在试点工作中,我们已经确定了多种新的血脂(鞘磷脂和神经酰胺类)和蛋白质生物标志物的COPD和肺气肿。我们假设这些生物标志物中的一些将是稳定的分子特征,可以识别症状前的当前和以前的吸烟者,他们有进展为症状性肺病(如COPD和肺气肿)的风险。我们的提案将测量来自三个国际纵向队列(COPDGene、SPIROMICS和Big 3)的先前采集的血液中的候选生物标志物,这些队列包含大量无COPD或肺气肿的症状前吸烟者或当前吸烟者,他们具有全基因组基因分型,并随访3-5年,进行广泛的临床表型分析,包括肺功能和qHRCT。第一个目标是确定哪些生物标志物与基线时未患COPD的患者的气流受限和肺气肿进展相关。第二个目标将调查这些签名是否随时间推移而稳定,并确定有助于生物标志物签名的遗传关联。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RUSSELL Paul BOWLER其他文献
RUSSELL Paul BOWLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RUSSELL Paul BOWLER', 18)}}的其他基金
Multi-omic networks associated with COPD progression in TOPMed Cohorts
TOPMed 队列中与 COPD 进展相关的多组学网络
- 批准号:
10592280 - 财政年份:2020
- 资助金额:
$ 39.51万 - 项目类别:
Multi-omic networks associated with COPD progression in TOPMed Cohorts
TOPMed 队列中与 COPD 进展相关的多组学网络
- 批准号:
10376750 - 财政年份:2020
- 资助金额:
$ 39.51万 - 项目类别:
Biomarker of Lung Disease in African Americans
非裔美国人肺部疾病的生物标志物
- 批准号:
9755496 - 财政年份:2018
- 资助金额:
$ 39.51万 - 项目类别:
Biomarker of Lung Disease in African Americans
非裔美国人肺部疾病的生物标志物
- 批准号:
10198999 - 财政年份:2018
- 资助金额:
$ 39.51万 - 项目类别:
Biomarker of Lung Disease in African Americans
非裔美国人肺部疾病的生物标志物
- 批准号:
10471583 - 财政年份:2018
- 资助金额:
$ 39.51万 - 项目类别:
Biomarker of Lung Disease in African Americans
非裔美国人肺部疾病的生物标志物
- 批准号:
9980976 - 财政年份:2018
- 资助金额:
$ 39.51万 - 项目类别:
Omics Data Integration to Identify Disease Pathways in COPD
组学数据整合识别慢性阻塞性肺病的疾病途径
- 批准号:
9440672 - 财政年份:2017
- 资助金额:
$ 39.51万 - 项目类别:
Sphingolipids and inflammatory biomarkers of COPD progression in healthy smokers
健康吸烟者 COPD 进展的鞘脂和炎症生物标志物
- 批准号:
9323560 - 财政年份:2015
- 资助金额:
$ 39.51万 - 项目类别:
New Strategies and Challenges in Lung Proteomics and Metabolomics
肺蛋白质组学和代谢组学的新策略和挑战
- 批准号:
8911120 - 财政年份:2015
- 资助金额:
$ 39.51万 - 项目类别:
Sphingolipids and inflammatory biomarkers of COPD progression in healthy smokers
健康吸烟者 COPD 进展的鞘脂和炎症生物标志物
- 批准号:
9144844 - 财政年份:2015
- 资助金额:
$ 39.51万 - 项目类别:
相似海外基金
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 39.51万 - 项目类别:
Fellowship
In depth proteomics-based dynamic profiling of blood proteins for colorectal cancer early detection
基于深度蛋白质组学的血液蛋白动态分析用于结直肠癌早期检测
- 批准号:
21K07408 - 财政年份:2021
- 资助金额:
$ 39.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Blood Proteins for early Discrimination of dEmentias
用于早期识别痴呆症的血液蛋白
- 批准号:
nhmrc : 1191861 - 财政年份:2020
- 资助金额:
$ 39.51万 - 项目类别:
International Collaborations
Nanomaterial based enrichment of blood proteins for cancer detection and monitoring
基于纳米材料的血液蛋白富集用于癌症检测和监测
- 批准号:
299939 - 财政年份:2013
- 资助金额:
$ 39.51万 - 项目类别:
Studentship Programs
SGER: Separation and Purification of High Molecular Weight Homologous Blood Proteins using IMAC
SGER:使用 IMAC 分离和纯化高分子量同源血液蛋白
- 批准号:
9904465 - 财政年份:1999
- 资助金额:
$ 39.51万 - 项目类别:
Standard Grant